by The global market for atopic dermatitis (AD) is ready to reach $ 22.4 billion in the sale of medicines within the decade, encouraged by the availability of targeted therapies, suggests market analysis.
A report from 2025 published by Globaldata, which analyzes the seven large markets of the US, the VK, France, Germany, Italy, Spain and Japan, the sale of the $ 22.4 billion sector will reach, an increase of $ 8.5 billion in 2023, a compound annual growth) of 10.2%. Although not as fast as the market for weight loss in the metabolic disease space, the growth of the advertising market is striking given the size of the market compared to other dermatology indications.
Advertisement: Offers with a high yield savings
Globaldata Healthcare Analyst, Filippos Maniatis, remarks: “AD is a growing market with an impressive pipeline of new products from current and future players in the field. The advertising space was previously dominated by broad -working immunomodulating agents, which is now slowly being replaced by the Pathiving. Behind the advertisement behind the advertisement and the approval of the approval of the paths behind the advertisement and the approval of the approval of the pathophiens behind the advertisement and the approval of the approval of the approval of the pathophiens of the path stop stops behind the advertisement and the approval.
Globaldata is the parent company of Pharmaceutical technology.
One of those targeted agents who has conquered the market is Regeneron and Sanofi’s jointly developed Dupixent (Dupilumab), first approved in the US in 2017. The blockbuster monoclonal antibody has seen its turnover on an annual atthing Athhanaases, including a lucrative athanseses, including a lucrative athaneseses, including a lucrative athaneseseses, including a lucrative athanesesesesesesesesesesesesesesesesesesesesesesesesesesesesesesesesesesesesaaseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseseshanaaseseses Lucrative Athing Athing Athing Athing Athing Athing Athing Athing Athing at Sales, including an assortment of sales. Dupix in 2024. Indication.
The report says that the gap of unfulfilled needs, which closes the courtesy of Sanofi and Regeneron, will shrink even further, depending on future approvals for more targeted therapies.
A modality set up as a future disruptor is the OX40 remedial class of medicines that work by inhibiting T-Celactivation and inflammation via the OX40 receptor on the immune cells. Pijpline candidates in development include Amgen and Kyowa Kirin’s Rocatinlimab, Sanofi’s Amlitelimab and Astria Therapeutics’ Telazrolimab.
Another class with a potential future in AD is Interleukine (IL) inhibitors. Leo Pharma, GSK and Nektar all have assets in clinical development.
ManIatis concludes: “Multiple pipeline in development can be further tackled. Such unfulfilled needs can be further addressed. Such unfulfilled needs include the lack of personalized treatments due to improved diagnostic methods, the high costs of current therapy options, the limited therapeutic options for chronic and management.”
“” Dupixent-Fuelled “Atopic Dermatitis market sale to reach $ 22.4 billion by 2033” was originally made and published by pharmaceutical technology, a brand of globaldata.
